174 related articles for article (PubMed ID: 26566925)
1. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
[TBL] [Abstract][Full Text] [Related]
3. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
4. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
Elena C; Passamonti F; Rumi E; Malcovati L; Arcaini L; Boveri E; Merli M; Pietra D; Pascutto C; Lazzarino M
Haematologica; 2011 Jan; 96(1):167-70. PubMed ID: 20884708
[TBL] [Abstract][Full Text] [Related]
5. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
6. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.
Brubaker LH; Brière J; Laszlo J; Kraut E; Landaw SA; Peterson P; Goldberg J; Donovan P
Arch Intern Med; 1982 Aug; 142(8):1533-7. PubMed ID: 7103635
[TBL] [Abstract][Full Text] [Related]
7. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
8. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
9. RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL.
Gilbertson DT; Monda KL; Bradbury BD; Collins AJ
Am J Kidney Dis; 2013 Nov; 62(5):919-28. PubMed ID: 23815986
[TBL] [Abstract][Full Text] [Related]
10. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
[TBL] [Abstract][Full Text] [Related]
11. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Tefferi A; Cervantes F; Mesa R; Passamonti F; Verstovsek S; Vannucchi AM; Gotlib J; Dupriez B; Pardanani A; Harrison C; Hoffman R; Gisslinger H; Kröger N; Thiele J; Barbui T; Barosi G
Blood; 2013 Aug; 122(8):1395-8. PubMed ID: 23838352
[TBL] [Abstract][Full Text] [Related]
12. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
13. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
[TBL] [Abstract][Full Text] [Related]
15. Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Bartoszko J; Panzarella T; McNamara CJ; Lau A; Schimmer AD; Schuh AC; Sibai H; Maze D; Yee KWL; Devlin R; Gupta V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):774-781. PubMed ID: 28711573
[TBL] [Abstract][Full Text] [Related]
16. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
17. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
[TBL] [Abstract][Full Text] [Related]
19. Impact of Hemoglobin Drop, Bleeding Events, and Red Blood Cell Transfusions on Long-term Mortality in Patients Undergoing Transaortic Valve Implantation.
Konigstein M; Havakuk O; Arbel Y; Finkelstein A; Ben-Assa E; Aviram G; Hareuveni M; Keren G; Banai S
Can J Cardiol; 2016 Oct; 32(10):1239.e9-1239.e14. PubMed ID: 26927856
[TBL] [Abstract][Full Text] [Related]
20. Coagulation defects do not predict blood product requirements during liver transplantation.
Massicotte L; Beaulieu D; Thibeault L; Roy JD; Marleau D; Lapointe R; Roy A
Transplantation; 2008 Apr; 85(7):956-62. PubMed ID: 18408574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
